Wall Street brokerages expect Mylan NV (NASDAQ:MYL) to post sales of $2.84 billion for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Mylan’s earnings, with estimates ranging from $2.75 billion to $2.90 billion. Mylan reported sales of $2.81 billion in the same quarter last year, which indicates a positive year over year growth rate of 1.1%. The company is expected to issue its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Mylan will report full year sales of $11.69 billion for the current year, with estimates ranging from $11.50 billion to $11.87 billion. For the next fiscal year, analysts forecast that the firm will report sales of $12.17 billion, with estimates ranging from $11.78 billion to $12.79 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Mylan.
Mylan (NASDAQ:MYL) last issued its earnings results on Tuesday, May 7th. The company reported $0.82 EPS for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The business had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.70 billion. During the same quarter last year, the firm posted $0.96 EPS. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year.
Several large investors have recently modified their holdings of the company. RPG Investment Advisory LLC grew its stake in shares of Mylan by 1.2% during the 2nd quarter. RPG Investment Advisory LLC now owns 214,812 shares of the company’s stock worth $4,113,000 after acquiring an additional 2,573 shares during the period. New Jersey Better Educational Savings Trust increased its position in shares of Mylan by 30.0% during the 2nd quarter. New Jersey Better Educational Savings Trust now owns 13,000 shares of the company’s stock valued at $248,000 after purchasing an additional 3,000 shares during the last quarter. Retirement Systems of Alabama increased its position in shares of Mylan by 121.2% during the 2nd quarter. Retirement Systems of Alabama now owns 531,186 shares of the company’s stock valued at $10,114,000 after purchasing an additional 291,086 shares during the last quarter. Supplemental Annuity Collective Trust of NJ increased its position in shares of Mylan by 60.0% during the 2nd quarter. Supplemental Annuity Collective Trust of NJ now owns 16,000 shares of the company’s stock valued at $305,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its position in shares of Mylan by 16.9% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 522,095 shares of the company’s stock valued at $14,796,000 after purchasing an additional 75,655 shares during the last quarter. 83.71% of the stock is currently owned by institutional investors.
MYL traded down $0.49 during trading hours on Wednesday, reaching $19.13. 8,265,778 shares of the stock traded hands, compared to its average volume of 6,454,997. The business’s fifty day moving average price is $18.28. The firm has a market cap of $10.11 billion, a P/E ratio of 4.18, a price-to-earnings-growth ratio of 1.01 and a beta of 1.76. Mylan has a fifty-two week low of $16.63 and a fifty-two week high of $39.59. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: Economic Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.